Send to:

Choose Destination

Links from Books

Drug class review. Triptans : final report update 4

Helfand, Mark
Peterson, Kim
McDonagh, Marian S
Drug class review. Triptans : final report update 4 [electronic resource] / Mark Helfand, Kim Peterson ; Marian McDonagh, principal investigator.
Other Title(s):
Drug class reviews
Country of Publication:
United States
Portland, Or. : Oregon Health & Science University, c2009.
Electronic Links:
Triptans, also called serotonin 5-hydroxytryptamine (5-HT)(1B/1D) agonists, are used to treat migraine and certain other headaches. Triptans act by binding to serotonin receptors in the brain, which leads to a reversal of blood vessel swelling. Triptans may be taken subcutaneously, orally as tablets, capsules, or quick-dissolving wafers, or intranasally as a spray. Currently, 7 triptans are available in the United States (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan), as well as a fixed-dose combination product containing sumatriptan plus naproxen. Comparing the clinical efficacy and harms of the different triptans has been an area of considerable interest to researchers and patients, but is complex because of the large variety of outcome measures that can be measured in studies. The purpose of this review is to compare the efficacy, effectiveness, and harms of triptans.
Clinical Trials as Topic
Drug Evaluation
Evidence-Based Medicine
Headache Disorders/drug therapy
Headache/drug therapy
United States
Publication Type(s):
Title from PDF cover.
"June 2009."
"Update 3: November 2005; Update 2: September 2004; Update 1: December 2003; Original Report: March 2003."
Includes bibliographical references.
The funding source, the Center for Evidence-based Policy, is supported by 14 organizations, including 13 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.
Mode of access: Internet.
101554797 [Electronic Resource]

Supplemental Content

Loading ...
Support Center